Can selenium levels act as a marker of colorectal cancer risk?
Selenium has attracted attention because of its antioxidant properties. Antioxidants protects cells from damage. Certain breakdown products of selenium are believed to prevent tumor growth by enhancing the immune cell activity and suppressing the development of tumor blood vessels. In this observational study, selenium level was measured in a series of patients from Poland and Estonia to determine a correlation between levels of this microelement and colorectal cancer risk.
A total of 169 colorectal cancer patients and 169 healthy controls were enrolled in the study after obtaining their informed consent. Selenium level in the blood serum was measured using Graphite Furnace Atomic Absorption Spectrometry (GFAAS). The statistical analysis was performed by Fisher’s exact test.
The threshold point of selenium level was 55 μg/l and 65 μg/l for Poland and Estonia respectively, for an increase in cancer risk. The lower levels of selenium were associated with greater risk of colorectal cancer.
The result reveals a significant strong association between low selenium level and the colorectal cancer risk in both Estonian and Polish populations.
- Rayman MP: Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 2005, 64:527–542. CrossRef
- Rayman MP: Selenium and human health. Lancet 2012, 379:1256–1268. CrossRef
- Fritz H, Kennedy D, Fergusson D, Fernandes R, Cooley K, Seely A, Sagar S, Wong R, Seely D: Selenium and lung cancer: a systematic review and meta analysis. PLoS One 2011, 6:e26259. CrossRef
- Rayman MP: Food-chain selenium and human health: emphasis on intake. Br J Nutr 2008, 100:254–268.
- Clark LC, Hixson LJ, Combs GF Jr, Reid ME, Turnbull BW, Sampliner RE: Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev 1993, 2:41–46.
- Schrauzer GN, White DA, Schneider CJ: Cancer mortality correlation studies, III. Statistical association with dietary selenium intakes. Bioinorg Chem 1977, 7:23–31. CrossRef
- Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, Marshall JR, Clark LC: Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002, 11:630–639.
- Takata Y, Kristal AR, King IB, Song X, Diamond AM, Foster CB, Hutter CM, Hsu L, Duggan DJ, Langer RD, Petrovitch H, Shikany JM, Vaughan TL, Lampe JW, Prentice RL, Peters U: Serum selenium, genetic variation in selenoenzymes, and risk of colorectal cancer: primary analysis from the Women’s Health Initiative Observational Study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2011, 20:1822–1830. CrossRef
- Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301:39–51. CrossRef
- Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH: Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011, 306:1549–1556. CrossRef
- Connelly-Frost A, Poole C, Satia JA, Kupper LL, Millikan RC, Sandler RS: Selenium, apoptosis, and colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2006, 15:486–493. CrossRef
- Reid ME, Duffield-Lillico AJ, Sunga A, Fakih M, Alberts DS, Marshall JR: Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int J Cancer 2006, 118:1777–1781. CrossRef
- Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS: Plasma selenium levels and the risk of colorectal adenomas. Nutr Cancer 1997, 7:125–129. CrossRef
- Ghadirian P, Maisonneuve P, Perret C, Kennedy G, Boyle P, Krewski D, Lacroix A: A case–control study of toenail selenium and cancer of the breast, colon, and prostate. Cancer Detect Prev 2000, 24:305–313.
- Psathakis D, Wedemeyer N, Oevermann E, Krug F, Siegers CP, Bruch HP: Blood selenium and glutathione peroxidase status in patients with colorectal cancer. Dis Colon Rectum 1998, 41:328–335. CrossRef
- Fernández-Bañares F, Cabré E, Esteve M, Mingorance MD, Abad-Lacruz A, Lachica M, Gil A, Gassull MA: Serum selenium and risk of large size colorectal adenomas in a geographical area with a low selenium status. Am J Gastroenterol 2002, 97:2103–2108.
- Salonen JT, Alfthan G, Huttunen JK, Puska P: Association between serum selenium and the risk of cancer. Am J Epidemiol 1984, 120:342–349.
- Zhao N: A case–control study of risk factors of colorectal cancer in Shanxi Province. Zhonghua Liu Xing Bing Xue Za Zhi 1990, 11:295–298.
- Nomura A, Heilbrun LK, Morris JS, Stemmermann GN: Serum selenium and the risk of cancer, by specific sites: case–control analysis of prospective data. J Natl Cancer Inst 1987, 79:103–108.
- Ścieszka M, Danch A, Machalski M, Drozdz M: Plasma selenium concentration in patients with stomach and colon cancer in the Upper Silesia. Neoplasma 1997, 44:395–397.
- van den Brandt PA, Goldbohm RA, Van’t Veer P, Bode P, Dorant E, Hermus RJ, Sturmans F: A prospective cohort study on toenail selenium levels and risk of gastrointestinal cancer. J Natl Cancer Inst 1993, 85:224–229. CrossRef
- Knekt P, Aromaa A, Maatela J, Alfthan G, Aaran RK, Teppo L, Hakama M: Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. Int J Cancer 1988, 42:846–850. CrossRef
- Méplan C, Crosley LK, Nicol F, Beckett GJ, Howie AF, Hill KE, Horgan G, Mathers JC, Arthur JR, Hesketh JE: Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). FASEB J 2007, 21:3063–3074. CrossRef
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/214/prepub
- Can selenium levels act as a marker of colorectal cancer risk?
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- April 2013
- Online ISSN
- BioMed Central
- Additional Links
- Cancer risk
- Dietary supplement
- Industry Sectors
- Marcin R Lener (1)
- Satish Gupta (1) (2)
- Rodney J Scott (3) (4)
- Martin Tootsi (5)
- Maria Kulp (6)
- Mari-Liis Tammesoo (5)
- Anu Viitak (6)
- Anders Metspalu (5)
- Pablo Serrano-Fernández (1)
- Józef Kładny (7)
- Katarzyna Jaworska-Bieniek (1) (2)
- Katarzyna Durda (1)
- Magdalena Muszyńska (1)
- Grzegorz Sukiennicki (1)
- Anna Jakubowska (1)
- Jan Lubiński (1)
- Author Affiliations
- 1. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, 70-115, Szczecin, Poland
- 2. Postgraduate School of Molecular Medicine Medical University of Warsaw, Żwirki i Wigury 61, 02-091, Warsaw, Poland
- 3. Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle, Newcastle, NSW, 2308, Australia
- 4. The Hunter Medical Research Institute, Newcastle, NSW, 2308, Australia
- 5. The Estonian Genome Center, University of Tartu, 23b Riia Str, Tartu, 51010, Estonia
- 6. Department of Analytical Chemistry, Tallinn University of Technology, Akadeemia tee 1512618, Tallinn, Estonia
- 7. Department of General and Oncological Surgery, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111, Szczecin, Poland